A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol

Abstract Background Median survival for patients with glioblastoma is less than a year. Standard treatment consists of surgical debulking if feasible followed by temozolomide chemo-radiotherapy. The immune checkpoint inhibitor ipilimumab targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) a...

Full description

Bibliographic Details
Main Authors: Nicholas F. Brown, Stasya M. Ng, Claire Brooks, Tim Coutts, Jane Holmes, Corran Roberts, Leena Elhussein, Peter Hoskin, Tim Maughan, Sarah Blagden, Paul Mulholland
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Cancer
Subjects:
Glioblastoma
Glioma
Ipilimumab
Temozolomide
Online Access:http://link.springer.com/article/10.1186/s12885-020-6624-y

Internet

http://link.springer.com/article/10.1186/s12885-020-6624-y

Similar Items